Why the study?
Does nephrology care improve outcomes and therapeutic goal compliance in patients with chronic kidney disease compared to primary care physician care?
Does nephrology care improve outcomes and therapeutic goal compliance in patients with chronic kidney disease compared to primary care physician care?
A national renal healthcare program in Uruguay demonstrated that nephrology care and the use of ACE inhibitors/ARBs are associated with better therapeutic target achievement and reduced risk of ESRD in patients with chronic kidney disease.
Nephrology care may aid CKD target achievement; hypothesis-generating and requires randomized confirmation before practice change.
BACKGROUND: Uruguay has implemented a chronic kidney disease (CKD) prevention program. AIMS: The objectives of the study are to assess the results of the National Renal Healthcare Program (NRHP). METHODS: This study is a cohort study of nondialysis-registered patients from October 2004 to March 2008. We made a comparison between patients under nephrology care (NC) or the care of a primary care physician (PCP; prereferral). In the outcome analysis, the primary endpoint was end-stage renal disease (ESRD) and the secondary endpoints were progression of CKD, compliance with the therapeutic goals and death. ESRD/mortality predictors were determined by Cox analysis. RESULTS: The study comprised 2,219 patients aged 67.4 +/- 13.5 years, of whom 52.5% were male, 42.1% hypertensive, 16.9% had diabetic nephropathy, and 61.3 and 21.4% were in CKD stages III and IV, respectively. At baseline, NC patients showed a better control than patients under the care of a PCP: systolic blood pressure > or =160 mm Hg (22.4 vs. 31.1%); total cholesterol <5.8 mmol/l (56.6 vs. 42.5%); and low-density lipoprotein cholesterol <2.9 mmol/l (41.2 vs. 29.1%). Control improved in patients under the care of a PCP according to years of enrollment. Outcome analysis (1,188 patients) showed a significant improvement in targets, with 56% of the patients stabilizing. CKD stage IV, diabetic nephropathy, proteinuria and hypertension increased the risk of ESRD; angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and age <65 years decreased the risk. CONCLUSIONS: Our results highlight the best management of CKD patients in both groups and the impact of the NC and renin-angiotensin-aldosterone system blockers.
No takes yet. Share an insight, caveat, or question.
Schwedt et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: